Aurora Cannabis reported strong financial results with significant revenue and EBITDA growth, positive free cash flow, and maintained a strong balance sheet. The company demonstrated leadership in the global medical cannabis market and succeeded in product expansion across key regions. However, there were challenges with declining consumer cannabis revenue, increased SG&A costs, and decreased margins in the plant propagation segment.

Company Guidance -

Q2 2026

During the fiscal first quarter of 2026, Aurora Cannabis Inc. reported strong financial performance, demonstrating a 17% increase in net revenue to $98 million, with global medical cannabis revenue rising by 37% and international revenue surging by 85%. The company achieved a significant improvement in its adjusted gross margin, which increased by 1,000 basis points to 52%, and adjusted EBITDA more than doubled to $11 million. Aurora maintained a strong cash balance of $186 million while operating its cannabis business debt-free, generating positive free cash flow of $9 million. Aurora's strategic focus on global medical cannabis, particularly in high-margin international markets such as Canada, Australia, Germany, Poland, and the U.K., underpinned its growth. The company also emphasized its competitive advantage through certifications like TGA GMP in Australia and EU GMP in Europe. The outlook for fiscal Q2 2026 anticipates continued revenue growth in the global medical cannabis segment, along with an increase in consolidated adjusted gross margins by 250 to 475 basis points, leading to sustained positive adjusted EBITDA.

Strong Financial Performance

Net revenue rose 17% to $98 million, with global medical cannabis revenue increasing 37%. International revenue grew 85%, and adjusted gross margin improved 1,000 basis points to 52%.

Significant EBITDA Growth

Adjusted EBITDA more than doubled to $11 million, representing a 209% increase from the year-ago period, indicating strong profitability growth.

Positive Free Cash Flow

Aurora generated positive free cash flow of $9 million, up 42% from the previous year, ending the quarter with $186 million in cash and no cannabis business debt.

Leadership in Global Medical Cannabis

Aurora is the largest Canadian exporter of high-quality medical cannabis, with leading market positions in Canada, Australia, Germany, Poland, and the U.K., supported by GMP-certified facilities.

Successful Product Expansion

Launch of two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country, and expansion in the U.K. with cultivar-specific inhalable cannabis extracts.

Aurora Cannabis (ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2026 (Q2)	0.01 / -	-0.159	―	―	―
Aug 06, 2025	2026 (Q1)	0.12 / -0.19	0.058	-425.00% (-0.25)
Jun 18, 2025	2025 (Q4)	0.09 / -0.25	-0.289	12.50% (+0.04)
Feb 05, 2025	2025 (Q3)	<0.01 / 0.41	-0.362	214.00% (+0.77)
Nov 06, 2024	2025 (Q2)	-0.08 / -0.16	0	―
Aug 07, 2024	2025 (Q1)	-0.13 / 0.06	-0.579	110.00% (+0.64)
Jun 20, 2024	2024 (Q4)	-0.13 / -0.29	9.86	-102.94% (-10.15)
Feb 08, 2024	2024 (Q3)	-0.10 / -0.36	-1.809	80.00% (+1.45)
Nov 09, 2023	2024 (Q2)	- / 0.00	-1.447	―
Sep 26, 2023	2023 (Q4)	- / -	-0.123	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$4.60	$4.24	-7.83%
Jun 18, 2025	$5.88	$4.68	-20.41%
Feb 05, 2025	$3.68	$5.37	+45.92%
Nov 06, 2024	$6.11	$5.12	-16.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.